Evaluating the Efficacy, Safety, and Tolerability of Serelaxin when Added to Standard Therapy in Asian Patients with Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.

Naoki Sato,Carolyn S. P. Lam,John R. Teerlink,Barry H. Greenberg,Hiroyuki Tsutsui,Byung-Hee Oh,Jian Zhang,Martin Lefkowitz,Tsushung A. Hua,Thomas Holbro,Miriam Marshood,Xing Li Wang,Junbo Ge
DOI: https://doi.org/10.1016/j.cardfail.2016.10.016
IF: 6.592
2016-01-01
Journal of Cardiac Failure
Abstract:Background: Acute heart failure (AHF), a common and growing health concern worldwide, is associated with high risk of post-discharge rehospitalization and mortality. Existing evidence indicates potential therapeutic benefits of serelaxin in Caucasian AHF patients, but corresponding data in Asians remain scarce. RELAX-AHF-ASIA, a multinational, randomized, double-blind, placebo-controlled, phase III trial, will evaluate the effects of serelaxin on symptom relief and clinical outcomes in Asian AHF patients, with the use of novel assessments. Methods and Results: Patients with AHF, systolic blood pressure >= 125 mm Hg, and mild to moderate renal dysfunction will be randomized within 16 hours of presentation to receive 48-hour intravenous infusion of 30 mu g . kg(-1) . d(-1) serelaxin or placebo in addition to standard therapy. The composite primary end point includes: (1) treatment success (moderate/marked improvement in patient-reported dyspnea and physician-assessed signs of congestion on day 2); (2) treatment failure (in-hospital worsening of signs and/ or symptoms of heart failure [HF] requiring intensification of intravenous HF therapy or mechanical ventilation, renal/circulatory support, rehospitalization due to HF/renal-failure, or death through day 5); and (3) unchanged status. Secondary end points include time to in-hospital worsening HF through day 5 and all cause and cardiovascular deaths through day 180. Conclusions: RELAX-AHF-ASIA, the largest randomized clinical trial in Asian AHF patients to date, has a novel composite primary end point and the potential to become a hallmark of AHF trials.
What problem does this paper attempt to address?